Celgene Corporation (NASDAQ:CELG) Q4 2014 Earnings Conference Call - Final Transcript
Jan 29, 2015 • 09:00 am ET
Good morning and welcome to the Celgene's Fourth Quarter 2014 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session at the end of the conference. I would like to remind you that this call is being recorded.
I would now like to turn the conference over to Patrick Flanigan, Vice President of Investor Relations at Celgene.
Thanks Nicole and welcome everyone to our fourth quarter and yearend earnings conference call. The press release reporting in our financial results in addition to the presentation for today's webcast can be accessed by going to the Investor Relations section of the corporate website at www.celgene.com.
Joining me in the room today with prepared remarks are Bob Hugin our Chairman and Chief Executive Officer; Peter Kellogg, our Chief Financial Officer, Jackie Fouse who is Global Head of our Hematology-Oncology Franchise, Scott Smith, Global Head of our Inflammation and Immunology Franchise and Mark Alles our President and Chief Operating Officer.
As a reminder, during today's call, we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent 10-Q on file with the SEC. These statements speak only as of today's date and we undertake no duty to update or revise them. Finally, a reconciliation of the adjusted financial measures to the most comparable GAAP measures are available as part of the earnings release.
I would now like to turn the call over to Bob.
Thank you, Patrick. And thank you, everyone, for joining us this morning. We look forward to providing you our perspectives on the outstanding results achieved in the fourth quarter and throughout the past year. These results and the strong operating momentum produced by all of our functions and geographies position us for sustained industry leading growth in 2015 and well beyond.
Peter, Jackie, Scott, and Mark will review the numerous accomplishments that have contributed to our exceptional financial and operating performance. They will also highlight the many significant milestones that reflect the extraordinary promise of 2015.
Though we have limited time to review the extensive progress advancing our increasingly broad and deep high potential pipeline, we are just beginning to see the substantial benefits of our focused commitment to our internal and collaborative research efforts.
In 2015, we plan to initiate eight new Phase I programs, reflecting the significant long-term growth potential of our pipeline, in addition to the numerous, near and medium term opportunities that will be discussed today.
We were energized by the promise of 2015 and we will provide additional insights and perspectives on our outlook for the year and on our 2020 targets.
I should note that early first quarter trends are providing a very strong start to the year. We are strategically we'll-positioned and committed to full capitalizing on the many opportunities to turn